New horizons in hepatitis C antiviral therapy with direct-acting antivirals

Alessio Aghemo, Raffaele De Francesco

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors. Two NS3/4A protease inhibitors have been approved recently, and more than 40 new NS3/4A, NS5A, or NS5B inhibitors are in development. These agents can achieve very high cure rates when combined with pegylated interferon-β and ribavirin and show promising clinical results when administered in all-oral combinations. In addition to the more canonical drug targets, new alternative viral targets for small-molecule drug development are emerging, such as p7 or NS4B and viral entry. Future research will need to define well-tolerated and cost-effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.

Original languageEnglish
Pages (from-to)428-438
Number of pages11
JournalHepatology
Volume58
Issue number1
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Hepatitis C
Antiviral Agents
Allosteric Site
Ribavirin
Protease Inhibitors
Hepacivirus
Pharmaceutical Preparations
Interferons
Liver Diseases
Catalytic Domain
Peptide Hydrolases
Genotype
Costs and Cost Analysis
Enzymes
Therapeutics
Proteins
Action Spectrum

ASJC Scopus subject areas

  • Hepatology

Cite this

New horizons in hepatitis C antiviral therapy with direct-acting antivirals. / Aghemo, Alessio; De Francesco, Raffaele.

In: Hepatology, Vol. 58, No. 1, 07.2013, p. 428-438.

Research output: Contribution to journalArticle

Aghemo, Alessio ; De Francesco, Raffaele. / New horizons in hepatitis C antiviral therapy with direct-acting antivirals. In: Hepatology. 2013 ; Vol. 58, No. 1. pp. 428-438.
@article{256c142655e743c2b4dfff05416ec10d,
title = "New horizons in hepatitis C antiviral therapy with direct-acting antivirals",
abstract = "Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors. Two NS3/4A protease inhibitors have been approved recently, and more than 40 new NS3/4A, NS5A, or NS5B inhibitors are in development. These agents can achieve very high cure rates when combined with pegylated interferon-β and ribavirin and show promising clinical results when administered in all-oral combinations. In addition to the more canonical drug targets, new alternative viral targets for small-molecule drug development are emerging, such as p7 or NS4B and viral entry. Future research will need to define well-tolerated and cost-effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.",
author = "Alessio Aghemo and {De Francesco}, Raffaele",
year = "2013",
month = "7",
doi = "10.1002/hep.26371",
language = "English",
volume = "58",
pages = "428--438",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - New horizons in hepatitis C antiviral therapy with direct-acting antivirals

AU - Aghemo, Alessio

AU - De Francesco, Raffaele

PY - 2013/7

Y1 - 2013/7

N2 - Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors. Two NS3/4A protease inhibitors have been approved recently, and more than 40 new NS3/4A, NS5A, or NS5B inhibitors are in development. These agents can achieve very high cure rates when combined with pegylated interferon-β and ribavirin and show promising clinical results when administered in all-oral combinations. In addition to the more canonical drug targets, new alternative viral targets for small-molecule drug development are emerging, such as p7 or NS4B and viral entry. Future research will need to define well-tolerated and cost-effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.

AB - Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors. Two NS3/4A protease inhibitors have been approved recently, and more than 40 new NS3/4A, NS5A, or NS5B inhibitors are in development. These agents can achieve very high cure rates when combined with pegylated interferon-β and ribavirin and show promising clinical results when administered in all-oral combinations. In addition to the more canonical drug targets, new alternative viral targets for small-molecule drug development are emerging, such as p7 or NS4B and viral entry. Future research will need to define well-tolerated and cost-effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.

UR - http://www.scopus.com/inward/record.url?scp=84879606466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879606466&partnerID=8YFLogxK

U2 - 10.1002/hep.26371

DO - 10.1002/hep.26371

M3 - Article

VL - 58

SP - 428

EP - 438

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -